Tag: Onchocerciasis Treatment Market Growth

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Onchocerciasis Treatment Market Growth Potential: How Will Market Size Shift Through 2030?

The onchocerciasis treatment market size has experienced robust expansion in recent times. This market is projected to expand from $1.11 billion in 2025 to $1.19 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 7.8%. Factors contributing to its historical growth include the restricted access to ivermectin and doxycycline in affected areas, a reliance on hospital-centric distribution methods, insufficient public knowledge regarding onchocerciasis management, underdeveloped preventive chemotherapy initiatives, and an over-reliance solely on oral drug forms.

The onchocerciasis treatment market is projected to experience robust expansion over the coming years. Its value is anticipated to reach $1.59 billion in 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This growth during the forecast period can be attributed to several factors, including the introduction of moxidectin and advanced long-acting formulations, the broadening reach of online and retail pharmacy distribution channels, the creation of novel combination therapies, increased financial support from governments and non-governmental organizations for eradication initiatives, and the implementation of community-focused preventive strategies. Key developments anticipated within this period include the scaling up of mass drug administration (MDA) programs, the formulation of treatments specifically for pediatric use and as fixed-dose combinations, a heightened emphasis on anti-wolbachia therapies, the integration of both oral and injectable treatment protocols, and an increase in community-based and government-backed treatment campaigns.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=36239505&type=smp&name=Onchocerciasis%20Treatment%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Onchocerciasis Treatment Market Expansion Drivers: What’s Shaping Future Growth?

The growing number of patients experiencing eye-related conditions is expected to boost the onchocerciasis treatment market in the future. Eye-associated issues cover a range of conditions affecting vision and ocular health, including infections, injuries, and chronic diseases like glaucoma or cataracts. This increase in patients with eye problems is primarily attributed to rising screen time and extended use of digital devices. Onchocerciasis treatment assists in preventing and managing vision loss and blindness by eliminating the parasitic infection that causes inflammation and damage to ocular tissues. For example, in May 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicated that about 20.5 million Americans over the age of 40 suffer from cataracts in at least one eye, accounting for 17.2% of that population. It is projected that nearly 30 million people will develop cataracts by 2028. Consequently, the increasing prevalence of eye-related conditions is fueling growth in the onchocerciasis treatment market. The increasing need for surgical procedures is anticipated to drive the onchocerciasis treatment market forward. Surgical procedures are medical interventions aimed at removing or repairing tissues damaged by disease, often employed when drug treatments are ineffective or when complications pose a threat to long-term health. This rise is fueled by the progression of onchocerciasis in some patients to advanced stages, where surgical intervention becomes essential to prevent permanent damage, such as vision loss or disfigurement. As a result, healthcare providers are expanding surgical services and investing in advanced techniques, thereby stimulating the overall market for onchocerciasis treatment. For instance, in June 2024, according to the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based professional body for board-certified aesthetic plastic surgeons, in 2023, nearly 35 million aesthetic procedures were performed worldwide, representing a 3.4% increase from 2022. The report also highlighted that surgical procedures rose by 5.5%, with more than 15.8 million procedures performed by plastic surgeons. Therefore, the increasing demand for surgical procedures is driving growth in the onchocerciasis treatment market.

Onchocerciasis Treatment Market Segmentation And Category Overview

The onchocerciasis treatment market covered in this report is segmented –

1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin

2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment

3) By Mode Of Administration: Oral, Injectables, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs

Subsegments:

1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations

2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments

3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas

4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs

Onchocerciasis Treatment Market Strategic Trends: What Defines The Next Growth Phase?

Leading companies in the onchocerciasis treatment market are concentrating on developing innovative antiparasitic medications to enhance treatment effectiveness and shorten its duration. Antiparasitic medications are drugs formulated to eliminate or inhibit parasites, such as worms and protozoa, that cause human infections. For instance, in December 2024, Medicines Development for Global Health (MDGH), an Australia-based non-profit biopharmaceutical company, obtained approval from the Ghana Food and Drugs Authority (FDA) for Moxidectin 2 mg oral tablets, designed to treat river blindness in individuals aged 4 years and older. This approval empowers Ghana to implement community-based mass drug administration programs using moxidectin, which offers superior efficacy and more prolonged effects compared to ivermectin. With this sanction, MDGH seeks to expand access to an effective new onchocerciasis treatment, thereby enabling large-scale community programs in endemic regions.

Onchocerciasis Treatment Market Competitive Analysis Of Leading Industry Participants

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

View The Full Onchocerciasis Treatment Market Report:

https://thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Onchocerciasis Treatment Market Geographic Landscape: Which Region Dominates Industry Growth?

North America was the largest region in the onchocerciasis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Onchocerciasis Treatment Market Expansion From $1.19 Billion In 2026 To $1.59 Billion In 2030

The market for onchocerciasis treatments has experienced robust expansion recently, with projections indicating growth from $1.11 billion in 2025 to $1.19 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.8%. This historical increase is largely driven by several key factors: the scarce supply of ivermectin and doxycycline in areas where the disease is prevalent, a heavy dependence on hospital-centered distribution networks, limited public understanding of how to manage the condition, insufficient implementation of preventive chemotherapy initiatives, and an exclusive reliance on oral medication formats.

The market for onchocerciasis treatments is anticipated to experience considerable expansion in the coming years, reaching $1.59 billion by 2030 with a compound annual growth rate of 7.4%. This projected growth during the forecast timeframe is driven by factors such as the launch of moxidectin and prolonged-release formulations, the widening availability through online and retail pharmacies, the creation of combination therapies, heightened government and NGO funding for eradication initiatives, and the establishment of community-focused preventive strategies. Key developments expected in the forecast period involve the scaling up of mass drug administration programs, the creation of pediatric and fixed-dose formulations, a rising emphasis on anti-Wolbachia therapies, the blending of oral and injectable treatment protocols, and the expansion of community-led and governmental treatment campaigns.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24634&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Onchocerciasis Treatment Market Expansion Supported By Key Demand Factors

The increasing number of individuals impacted by ocular conditions is anticipated to drive the expansion of the onchocerciasis treatment market in the coming period. Ocular conditions encompass a range of disorders affecting vision and eye health, such as infections, injuries, and long-term diseases like glaucoma or cataracts. This rise in affected patients is largely attributed to heightened screen usage and extended exposure to digital devices. Onchocerciasis treatment aids in averting and controlling vision impairment and blindness in individuals by eradicating the parasitic infection that induces inflammation and harm to eye tissues. By way of example, in May 2024, the Centers for Disease Control and Prevention (CDC), a US-based public health body, reported that approximately 20.5 million Americans aged over 40 have cataracts in one eye, representing 17.2% of that demographic. It is estimated that nearly 30 million individuals will develop cataracts by 2028. Consequently, the growing frequency of eye-related disorders is fueling the onchocerciasis treatment market.

The growing need for surgical procedures is projected to stimulate the onchocerciasis treatment market’s growth moving forward. Surgical procedures are medical interventions designed to extract or fix tissues compromised by disease, frequently applied when pharmaceutical treatments are unsuccessful or when complications threaten lasting health. This escalation stems from the progression of onchocerciasis in certain patients to severe phases, where surgical action is needed to avoid permanent harm, like vision loss or deformity. In response, healthcare providers are broadening surgical offerings and investing in cutting-edge techniques, thereby enhancing the onchocerciasis treatment market. For instance, in June 2024, the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based professional association for board-certified cosmetic plastic surgeons, indicated that in 2023, almost 35 million aesthetic procedures were carried out globally, a 3.4% rise from 2022. The report further noted that surgical interventions grew by 5.5%, with over 15.8 million procedures executed by plastic surgeons. Hence, the increasing demand for surgical procedures is driving expansion in the onchocerciasis treatment market.

Onchocerciasis Treatment Market Segment Analysis And Revenue Opportunities

The onchocerciasis treatment market covered in this report is segmented –

1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin

2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment

3) By Mode Of Administration: Oral, Injectables, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs

Subsegments:

1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations

2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments

3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas

4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs

Onchocerciasis Treatment Market Growth Trends Influencing Competitive Dynamics

Leading companies in the onchocerciasis treatment space are prioritizing the development of innovative antiparasitic drugs aimed at boosting therapeutic outcomes and shortening treatment timelines. These antiparasitic agents work by eradicating or suppressing parasites such as protozoa and worms that cause human infections. A notable example occurred in December 2024, when Medicines Development for Global Health (MDGH), an Australian nonprofit biopharmaceutical organization, secured approval from Ghana’s Food and Drugs Authority (FDA) for Moxidectin 2 mg oral tablets. This medication is indicated for treating river blindness in patients aged 4 years and older. The clearance allows Ghana to initiate community-wide mass drug administration campaigns using moxidectin, which demonstrates enhanced effectiveness and prolonged action compared to ivermectin. Through this regulatory milestone, MDGH seeks to broaden availability of a potent new therapy for onchocerciasis, facilitating large-scale community-based interventions in endemic areas.

Onchocerciasis Treatment Market Leading Players Shaping Industry Direction

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

Access The Complete Onchocerciasis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Onchocerciasis Treatment Market Geographic Distribution And Regional Opportunities

North America was the largest region in the onchocerciasis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Estimated Growth In Market Size Of The Onchocerciasis Treatment Market During 2026–2030?

The onchocerciasis treatment market size has observed substantial growth in recent years. It is projected to increase from $1.11 billion in 2025 to $1.19 billion in 2026, reflecting a compound annual growth rate (CAGR) of 7.8%. This historic growth can be attributed to several factors, including the limited availability of ivermectin and doxycycline in endemic regions, a reliance on hospital-based distribution channels, low awareness concerning onchocerciasis management, inadequate preventive chemotherapy programs, and a dependency on oral formulations only.

The onchocerciasis treatment market is projected to experience substantial expansion over the coming years. It is anticipated to reach a valuation of $1.59 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. This anticipated growth during the forecast period can be attributed to several factors, including the introduction of moxidectin and long-acting formulations, the broadening of online and retail pharmacy distribution channels, the advancement of combination therapies, enhanced funding from government and non-governmental organizations (NGOs) for eradication initiatives, and the implementation of community-based preventive approaches. Key trends expected during this period involve the scaling up of mass drug administration (MDA) programs, the creation of pediatric and fixed-dose formulations, a greater emphasis on anti-wolbachia therapies, the incorporation of both oral and injectable treatment regimens, and an increase in community-based and government-backed treatment campaigns.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24634&type=smp

Which Major Factors Are Contributing To The Development Of The Onchocerciasis Treatment Market?

The rising number of individuals facing eye-related issues is projected to boost the growth of the onchocerciasis treatment market in the future. Eye-associated issues cover various conditions impacting vision and ocular health, including infections, injuries, and chronic ailments such as glaucoma or cataracts. The increase in patients with eye-related problems is mainly due to heightened screen time and extended exposure to digital devices. Onchocerciasis treatment works by eradicating the parasitic infection that causes inflammation and damage to ocular tissues, thereby assisting in the prevention and management of vision loss and blindness. For example, according to the Centers for Disease Control and Prevention (CDC) in **May 2024**, around **20.5 million Americans** over the age of 40 had cataracts in at least one eye, accounting for **17.2%** of that demographic. It is foreseen that nearly **30 million** people will develop cataracts by **2028**. Consequently, the increasing prevalence of eye conditions is fueling expansion in the onchocerciasis treatment market. The growing demand for surgical interventions is expected to drive the onchocerciasis treatment market forward. Surgical procedures refer to medical operations designed to remove or repair tissues damaged by disease, frequently utilized when drug therapies are ineffective or when complications pose a threat to long-term health. This increase is driven by the progression of onchocerciasis in some patients to advanced stages, where surgery becomes essential to prevent permanent damage like vision loss or disfigurement. As a result, healthcare providers are expanding surgical capabilities and investing in advanced techniques, thus boosting the overall market for onchocerciasis treatment. For instance, in **June 2024**, the International Society of Aesthetic Plastic Surgery (ISAPS) reported that in **2023**, nearly **35 million** aesthetic procedures were conducted globally, representing a **3.4%** increase from **2022**. The report also indicated that surgical procedures climbed by **5.5%**, with more than **15.8 million** procedures performed by plastic surgeons. Therefore, the rising requirement for surgical procedures is propelling growth in the onchocerciasis treatment market.

How Is The Onchocerciasis Treatment Market Structured Across Different Market Segments?

The onchocerciasis treatment market covered in this report is segmented –

1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin

2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment

3) By Mode Of Administration: Oral, Injectables, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs

Subsegments:

1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations

2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments

3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas

4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs

What Trends Are Influencing The Onchocerciasis Treatment Market?

Leading companies active in the onchocerciasis treatment market are prioritizing the development of novel antiparasitic medicines to improve the efficacy and reduce the duration of treatment. Antiparasitic medications are pharmaceutical agents designed to eliminate or inhibit parasites such as worms and protozoa, which are known to cause infections in humans. For instance, in December 2024, Medicines Development for Global Health (MDGH), an Australia-based non-profit biopharmaceutical company, obtained approval from the Ghana Food and Drugs Authority (FDA) for Moxidectin 2 mg oral tablets intended for the treatment of river blindness in individuals aged 4 years and older. This authorization allows Ghana to implement community-based mass drug administration programs using moxidectin, which provides enhanced efficacy and more prolonged effects compared to ivermectin. With this recent approval, MDGH aims to expand access to an effective new therapy for onchocerciasis, enabling large-scale community initiatives in endemic regions.

Who Are The Major Companies Operating In The Onchocerciasis Treatment Market?

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

Access The Complete Onchocerciasis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report

Which Region Stands As The Largest Contributor To The Onchocerciasis Treatment Market?

North America was the largest region in the onchocerciasis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Onchocerciasis Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24634&type=smp

Browse Through More Reports Similar to the Global Onchocerciasis Treatment Market 2026, By The Business Research Company

Oncology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report

Oncology Companion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Oncologists Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncologists-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Onchocerciasis Treatment Market Grow Between 2026 And 2030?

The onchocerciasis treatment market size has experienced significant expansion over recent years. It is anticipated to expand from $1.11 billion in 2025 to $1.19 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. This historical growth can be ascribed to several factors, including the constrained supply of ivermectin and doxycycline in regions affected by the disease, a reliance on distribution channels primarily based in hospitals, a general lack of public awareness regarding onchocerciasis management, inadequacies in preventive chemotherapy programs, and an exclusive dependence on oral formulations.

The onchocerciasis treatment market size is anticipated to experience robust expansion in the coming years. This market is projected to reach $1.59 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.4%. The expected growth during this forecast period stems from factors such as the introduction of moxidectin and long-acting formulations, the widening of online and retail pharmacy distribution channels, the creation of combination therapies, augmented government and NGO financial support for eradication initiatives, and the implementation of community-based preventive strategies. Key developments anticipated over the forecast period encompass the broadening of mass drug administration (mda) programs, the formulation of pediatric and fixed-dose treatments, a heightened emphasis on anti-wolbachia therapies, the integration of both oral and injectable treatment protocols, and an increase in community-based and government-backed treatment campaigns.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24634&type=smp

Which Primary Drivers Are Impacting The Onchocerciasis Treatment Market Growth?

The increasing number of patients experiencing eye-related conditions is anticipated to boost the onchocerciasis treatment market moving forward. These eye-associated issues encompass various conditions impacting vision and ocular health, such as infections, injuries, and chronic ailments like glaucoma or cataracts. The rise in individuals with these conditions is primarily linked to greater screen time and extended exposure to digital devices. Onchocerciasis treatment aids in preventing and managing vision loss and blindness by eliminating the parasitic infection responsible for inflammation and damage to ocular tissues. For example, the Centers for Disease Control and Prevention (CDC), a US public health agency, reported in May 2024 that approximately 20.5 million Americans over 40 years old have cataracts in at least one eye, representing 17.2% of that demographic. Projections indicate that nearly 30 million individuals will develop cataracts by 2028. Consequently, the growing prevalence of eye conditions is fueling expansion in the onchocerciasis treatment market. The increasing need for surgical interventions is projected to stimulate growth in the onchocerciasis treatment market in the future. Surgical procedures involve medical actions aimed at removing or repairing disease-damaged tissues, frequently employed when pharmaceutical treatments are ineffective or when complications threaten long-term health. This surge is attributed to the progression of onchocerciasis in some patients to advanced stages, necessitating surgical intervention to avert permanent harm, such as vision impairment or disfigurement. Consequently, healthcare providers are expanding their surgical offerings and investing in advanced techniques, thereby enhancing the overall market for onchocerciasis treatment. For instance, in June 2024, the International Society of Aesthetic Plastic Surgery (ISAPS), a US-based professional organization for board-certified aesthetic plastic surgeons, noted that nearly 35 million aesthetic procedures were performed globally in 2023, marking a 3.4% increase from 2022. The report further indicated a 5.5% rise in surgical procedures, with over 15.8 million procedures conducted by plastic surgeons. Thus, the growing demand for surgical procedures is propelling the onchocerciasis treatment market’s expansion.

How Is The Onchocerciasis Treatment Market Organized By Segment Classification?

The onchocerciasis treatment market covered in this report is segmented –

1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin

2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment

3) By Mode Of Administration: Oral, Injectables, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs

Subsegments:

1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations

2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments

3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas

4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs

Which Trends Are Shaping The Onchocerciasis Treatment Market?

Leading companies operating in the onchocerciasis treatment market are prioritizing the development of innovative antiparasitic drugs to enhance the effectiveness of treatment and decrease its duration. Antiparasitic medications are pharmaceuticals specifically designed to eliminate or inhibit parasites like worms and protozoa, which are known to cause human infections. For instance, in December 2024, Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical company based in Australia, secured approval from the Ghana Food and Drugs Authority (FDA) for its Moxidectin 2 mg oral tablets, intended for treating river blindness in individuals aged 4 years and older. This authorization allows Ghana to conduct community-based mass drug administration programs using moxidectin, which provides superior efficacy and more prolonged effects compared to ivermectin. With this approval, MDGH aims to expand access to an effective new therapy for onchocerciasis, thereby enabling large-scale community initiatives in endemic regions.

Who Are The Industry Participants Involved In The Onchocerciasis Treatment Market?

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

Get The Full Onchocerciasis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report

Where Is The Onchocerciasis Treatment Market Primarily Concentrated By Region?

North America was the largest region in the onchocerciasis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Onchocerciasis Treatment Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report

Browse Through More Reports Similar to the Global Onchocerciasis Treatment Market 2026, By The Business Research Company

Oncology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report

Oncology Companion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Oncologists Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncologists-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Expected Market Size Of The Onchocerciasis Treatment Market From 2026 To 2030?

The onchocerciasis treatment market has experienced robust growth recently. This market is projected to expand from $1.11 billion in 2025 to $1.19 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 7.8%. Factors contributing to its historical expansion include the restricted access to ivermectin and doxycycline in areas where the disease is prevalent, a reliance on hospital-centric distribution channels, insufficient understanding of onchocerciasis management, shortcomings in preventive chemotherapy initiatives, and an exclusive reliance on oral drug formulations.

The onchocerciasis treatment market size is anticipated to experience robust growth in the upcoming years, with an expected increase to $1.59 billion by 2030, reflecting a compound annual growth rate (CAGR) of 7.4%. The expansion projected for this period can be attributed to several factors, including the introduction of moxidectin and long-acting formulations, the broader availability through online and retail pharmacy distribution, the development of combination therapies, augmented funding from governments and NGOs for eradication initiatives, and the implementation of community-based preventive approaches. Key trends identified for the forecast period involve the broadening of mass drug administration (MDA) programs, the creation of pediatric and fixed-dose formulations, an increased emphasis on anti-Wolbachia therapies, the integration of both oral and injectable treatment regimens, and the growth of treatment campaigns supported by communities and governments.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24634&type=smp

What Drivers Are Influencing The Onchocerciasis Treatment Market?

An anticipated increase in individuals experiencing eye-related conditions is projected to fuel the expansion of the onchocerciasis treatment market in the coming years. These eye-related problems encompass diverse ailments impacting sight and ocular well-being, such as infections, injuries, and persistent conditions like glaucoma or cataracts. This increase in patients with eye conditions is largely attributed to elevated screen usage and extended contact with digital screens. Treatment for onchocerciasis aids in averting and handling sight impairment and blindness by eradicating the parasitic infection responsible for ocular tissue inflammation and damage. For example, data from May 2024, provided by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, indicated that approximately 20.5 million Americans aged over 40 had cataracts in at least one eye, representing 17.2% of that demographic. Projections suggest that close to 30 million individuals will develop cataracts by 2028. Consequently, the growing occurrence of conditions affecting the eyes is fueling expansion within the onchocerciasis treatment market.

Which Segments Are Included In The Analysis Of The Onchocerciasis Treatment Market?

The onchocerciasis treatment market covered in this report is segmented –

1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin

2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment

3) By Mode Of Administration: Oral, Injectables, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs

Subsegments:

1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations

2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments

3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas

4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs

Which Trends Are Impacting The Growth Of The Onchocerciasis Treatment Market?

Leading companies within the onchocerciasis treatment market are concentrating on developing innovative antiparasitic drugs to enhance therapeutic effectiveness and reduce treatment duration. Antiparasitic medications are pharmaceutical agents specifically formulated to eliminate or inhibit parasites like worms and protozoa that cause infections in humans. For example, in December 2024, Medicines Development for Global Health (MDGH), an Australia-based non-profit biopharmaceutical company, obtained approval from the Ghana Food and Drugs Authority (FDA) for Moxidectin 2 mg oral tablets to treat river blindness in individuals aged 4 years and older. This authorization allows Ghana to implement community-based mass drug administration programs utilizing moxidectin, which provides greater efficacy and more prolonged effects compared to ivermectin. With this approval, MDGH aims to broaden access to an effective new treatment for onchocerciasis, thereby enabling large-scale community programs in endemic regions.

Which Key Industry Participants Are Active In The Onchocerciasis Treatment Market?

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

Read the full onchocerciasis treatment market report here:

https://www.thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Onchocerciasis Treatment Market?

North America was the largest region in the onchocerciasis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Onchocerciasis Treatment Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24634&type=smp

Browse Through More Reports Similar to the Global Onchocerciasis Treatment Market 2026, By The Business Research Company

Oncology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report

Oncology Companion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Oncologists Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncologists-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the onchocerciasis treatment market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Onchocerciasis Treatment Market?

The onchocerciasis treatment market has observed considerable expansion over recent years. Its value is projected to rise from $1.11 billion in 2025 to $1.19 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.8%. The growth seen historically can be attributed to several factors, including the limited availability of ivermectin and doxycycline in endemic regions, a reliance on hospital-based distribution channels, low awareness concerning onchocerciasis management, inadequate preventive chemotherapy programs, and a dependency solely on oral formulations.

The onchocerciasis treatment market is projected to experience substantial expansion in the coming years. This market is predicted to reach $1.59 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.4%. Several factors are expected to drive this growth during the forecast period, including the introduction of moxidectin and new long-acting formulations, the broadening reach of online and retail pharmacy distribution channels, the advancement of combination therapies, increased financial support from government bodies and NGOs for eradication initiatives, and the implementation of community-focused preventive strategies. Key trends anticipated during this period encompass the expansion of mass drug administration (mda) programs, the creation of pediatric and fixed-dose drug formulations, a heightened emphasis on anti-wolbachia therapies, the integration of both oral and injectable treatment protocols, and the rise of treatment campaigns supported by communities and governments.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24634&type=smp

Which Drivers Are Supporting The Rise Of The Onchocerciasis Treatment Market?

An increase in individuals experiencing eye-related problems is anticipated to drive the expansion of the onchocerciasis treatment market. These problems encompass various conditions impacting sight and eye health, such as infections, injuries, and long-term ailments like glaucoma or cataracts. The main reason for this surge in patients is greater screen time and extended contact with digital screens. Treatments for onchocerciasis aid in preventing and addressing vision impairment and blindness by eradicating the parasitic infection responsible for inflammation and harm to eye tissues. For example, in May 2024, data from the Centers for Disease Control and Prevention (CDC), a US public health organization, indicated that approximately 20.5 million Americans aged over 40 had cataracts in at least one eye, representing 17.2% of that demographic. Projections suggest that close to 30 million people will develop cataracts by 2028. Consequently, the growing occurrence of eye conditions is fueling the expansion of the onchocerciasis treatment market. Anticipated expansion of the onchocerciasis treatment market is linked to an increasing need for surgical interventions. These procedures involve medical operations designed to excise or mend tissues harmed by illness, frequently employed when pharmaceutical remedies fail or when long-term health is jeopardized by complications. The uptick is primarily due to onchocerciasis advancing to severe stages in certain individuals, necessitating surgery to avert irreversible harm like vision impairment or physical disfigurement. Consequently, medical service providers are enhancing surgical offerings and allocating resources to sophisticated methods, which in turn stimulates the broader market for onchocerciasis treatment. For example, in June 2024, the International Society of Aesthetic Plastic Surgery (ISAPS), a US professional organization for certified aesthetic plastic surgeons, reported that almost 35 million aesthetic procedures were carried out globally in 2023, showing a 3.4% rise from 2022. The same report also noted a 5.5% increase in surgical procedures, with over 15.8 million performed by plastic surgeons. Thus, the heightened requirement for surgical interventions is propelling expansion in the onchocerciasis treatment market.

What Leading Segments Are Studied In The Onchocerciasis Treatment Market?

The onchocerciasis treatment market covered in this report is segmented –

1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin

2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment

3) By Mode Of Administration: Oral, Injectables, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs

Subsegments:

1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations

2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments

3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas

4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs

Which Trends Are Guiding The Evolution Of The Onchocerciasis Treatment Market?

Companies prominent in the onchocerciasis treatment market are prioritizing the development of innovative antiparasitic drugs to enhance the effectiveness and decrease the duration of treatment. Antiparasitic medications are agents specifically designed to eliminate or suppress parasites like worms and protozoa that cause human infections. For example, in December 2024, Medicines Development for Global Health (MDGH), an Australia-based non-profit biopharmaceutical organization, obtained approval from the Ghana Food and Drugs Authority (FDA) for its Moxidectin 2 mg oral tablets for treating river blindness in individuals aged 4 years and older. This approval empowers Ghana to implement community-based mass drug administration programs using moxidectin, which provides greater efficacy and more lasting effects compared to ivermectin. With this authorization, MDGH aims to expand access to an effective new onchocerciasis treatment, enabling large-scale community initiatives in regions where the disease is endemic.

Which Major Industry Participants Are Leading The Onchocerciasis Treatment Market Growth?

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report

Which Region Is Expected To Experience The Fastest Growth In The Onchocerciasis Treatment Market?

North America was the largest region in the onchocerciasis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Onchocerciasis Treatment Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=24634&type=smp

Browse Through More Reports Similar to the Global Onchocerciasis Treatment Market 2026, By The Business Research Company

Oncology Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report

Oncology Companion Diagnostics Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Oncologists Market Report 2026

https://www.thebusinessresearchcompany.com/report/oncologists-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Is The Onchocerciasis Treatment Market Size Likely To Evolve From 2025 Through 2034?

The onchocerciasis treatment market size has shown substantial growth recently. It is forecast to increase from $1.03 billion in 2024 to $1.11 billion in 2025, achieving a compound annual growth rate (CAGR) of 7.8%. The expansion observed historically can be linked to a rise in individuals experiencing eye-related conditions, an uptick in parasitic infections, an increase in the availability of targeted treatment centers, a surge in awareness campaigns, and an expanding older population.

The onchocerciasis treatment market is projected to experience substantial expansion in the coming years. It is forecast to reach $1.48 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 7.5%. This anticipated growth is driven by factors such as an increasing incidence in affected areas, a greater need for surgical interventions, improvements in healthcare facilities, a rising occurrence of long-term illnesses, and increased spending in the healthcare sector. Key trends during this period are expected to encompass the adoption of single-dose treatments, progress in macrocyclic lactone formulations, the introduction of therapies aimed at Wolbachia, the incorporation of artificial intelligence (AI) into drug development, and the creation of treatments specifically for children.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24634&type=smp

Which Drivers Are Shaping The Onchocerciasis Treatment Industry’s Market Share?

An increase in individuals experiencing eye-related problems is anticipated to fuel the expansion of the onchocerciasis treatment market in the future. These problems encompass various conditions impacting sight and eye well-being, such as infections, injuries, and persistent diseases like glaucoma or cataracts. The rise in patients with eye conditions primarily stems from increased screen usage and extended contact with digital screens. Onchocerciasis therapy assists in averting and handling vision impairment and blindness in affected individuals by eradicating the parasitic infection responsible for inflammation and harm to eye tissues. For example, as reported in May 2024 by the Centers for Disease Control and Prevention (CDC), a US-based public health agency, approximately 20.5 million Americans aged over 40 suffer from cataracts in at least one eye, representing 17.2% of that demographic. Furthermore, projections indicate that close to 30 million individuals will develop cataracts by 2028. Consequently, the growing occurrence of eye-related ailments is stimulating the expansion of the onchocerciasis treatment market.

What Are The Major Segments Identified In The Onchocerciasis Treatment Market?

The onchocerciasis treatment market covered in this report is segmented –

1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin

2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment

3) By Mode Of Administration: Oral, Injectables, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs

Subsegments:

1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations

2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments

3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas

4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs

What Trends Are Redefining The Onchocerciasis Treatment Market Dynamics?

Major companies operating in the onchocerciasis treatment market are concentrating on developing new antiparasitic medications to enhance treatment effectiveness and decrease its duration. Antiparasitic medications are drugs engineered to eliminate or suppress parasites, such as worms and protozoa, which cause human infections. For example, in December 2024, Medicines Development for Global Health (MDGH), an Australia-based non-profit biopharmaceutical company, obtained approval from the Ghana Food and Drugs Authority (FDA) for Moxidectin 2 mg oral tablets to treat river blindness in individuals aged 4 years and older. This approval empowers Ghana to implement community-based mass drug administration programs using moxidectin, which provides superior efficacy and more enduring effects compared to ivermectin. With this approval, MDGH aims to broaden access to an effective new onchocerciasis treatment, facilitating large-scale community initiatives in endemic regions.

Which Key Players Are Driving Competition In The Onchocerciasis Treatment Market?

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report

What Regional Growth Trends Are Shaping The Onchocerciasis Treatment Market Outlook?

North America was the largest region in the onchocerciasis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Onchocerciasis Treatment Market Report:

https://www.thebusinessresearchcompany.com/customise?id=24634&type=smp

Browse Through More Reports Similar to the Global Onchocerciasis Treatment Market 2025, By The Business Research Company

Oncology Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-drugs-global-market-report

Oncology Companion Diagnostics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncology-companion-diagnostics-global-market-report

Oncologists Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/oncologists-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Onchocerciasis Treatment Industry?

The market size for onchocerciasis treatment has experienced robust growth in the past few years. It is projected to expand from $1.03 billion in 2024 to $1.11 billion in 2025, boasting a compound annual growth rate (CAGR) of 7.8%. The previous growth trajectory can be accounted for by factors such as a rise in cases of eye-related conditions, a surge in parasitic infections, an increase in the quantity of specialized treatment facilities, an escalation in educational outreach efforts, and a growth in the aging population.

The market for onchocerciasis treatment is predicted to significantly expand in the upcoming years, projected to reach $1.48 billion in 2029 with a compound annual growth rate (CAGR) of 7.5%. The expected growth in this period is due to a number of factors including the increased frequency of the disease in endemic regions, a surge in demand for surgical interventions, enhancements in healthcare structures, a rise in the incidence of chronic illnesses and escalating investments in healthcare. Notable trends anticipated within this period encompass a movement towards single-dose treatment plans, progress in macrocyclic lactone formulations, the introduction of Wolbachia-targeting therapies, the implementation of artificial intelligence (AI) in medication discovery, and the evolution of treatments specifically designed for children.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24634&type=smp

What Forces Are Driving The Growth Of The Onchocerciasis Treatment Industry?

The increasing number of individuals dealing with vision problems is expected to influence the growth of the onchocerciasis treatment market in a positive way. Problems related to eyes can range from infections and injuries to chronic illnesses like glaucoma or cataracts. Enhanced screen time and overexposure to digital devices are primary reasons for the surge in cases. Treating onchocerciasis helps in preventing vision loss or blindness in patients by removing the parasitic infection causing inflammation and damage to eye tissues. For example, data from the Centers for Disease Control and Prevention (CDC) reveals that approximately 20.5 million Americans above 40 years have at least one eye affected by cataracts, making up 17.2% of this age group, as of May 2024. Predictions suggest that close to 30 million people may develop cataracts by 2028. Hence, the growing occurrence of eye-related problems largely contributes to the growth of the onchocerciasis treatment market. Expansion In Surgical Measures Leads To Market Growth Due To Escalating Cases Needing Complex Disease Management

What Is The Overview Of Market Segmentation In The Onchocerciasis Treatment Industry?

The onchocerciasis treatment market covered in this report is segmented –

1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin

2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment

3) By Mode Of Administration: Oral, Injectables, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs

Subsegments:

1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations

2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments

3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas

4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs

What Future Market Trends Are Projected For The Onchocerciasis Treatment Industry?

Leading companies in the onchocerciasis treatment market are concentrating their efforts on creating new antiparasitic drugs to increase the effectiveness of treatment and decrease the treatment duration. Antiparasitic drugs are engineered to counter or eradicate parasites that lead to infections in humans, such as worms and protozoa. For example, in December 2024, the Ghana Food and Drugs Authority gave approval to Medicines Development for Global Health (MDGH) – a non-profit biopharmaceutical enterprise located in Australia – for their Moxidectin 2 mg oral tablets. These are designed to treat river blindness in people who are at least 4 years old. As a result of the approval, Ghana has the ability to initiate mass drug administration programs at a community level with moxidectin, a medication that is more effective and has longer-lasting impacts than its counterpart, ivermectin. With the green light from the FDA, MDGH has the goal of increasing the availability of this new, effective treatment for onchocerciasis, which would enable wide-scale community initiatives in regions where the disease is endemic.

Who Are The Primary Players Operating Across The Global Onchocerciasis Treatment Market?

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report

Which Region Offers The Most Growth Potential For The Onchocerciasis Treatment Market Through 2029?

North America was the largest region in the onchocerciasis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24634&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has the Onchocerciasis Treatment Market Grown from 2024 to 2025?

In recent times, the onchocerciasis treatment industry has experienced significant growth. The market size is projected to expand from $1.03 billion in 2024 to about $1.11 billion in 2025, indicating a compound annual growth rate (CAGR) of 7.8%. A surge in the number of individuals dealing with vision-related problems, a rise in parasitic infections, an escalated number of specialized treatment facilities, improved awareness through education campaigns, and the increase in the elderly population contribute to this historical growth.

What Growth Rate Is Anticipated for the Onchocerciasis Treatment Market in the Coming Years?

The market for onchocerciasis treatment is projected to witness substantial expansion in the approaching years, rising to a worth of $1.48 billion in 2029 with a 7.5% Compound Annual Growth Rate (CAGR). Factors contributing to this growth during the forecast period include a surge in prevalence in areas where the disease is endemic, an increased demand for surgical procedures, an enhancement in healthcare facilities, an upsurge in chronic diseases, and increased investment in healthcare. The forecast period will also see major trends such as a move towards single-dose treatment plans, advancements in macrocyclic lactone formulations, the rise of therapies targeting Wolbachia, integration of artificial intelligence in drug discovery, and the culmination of treatments specifically designed for children.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24634&type=smp

Who Are the Leading Companies in the Onchocerciasis Treatment Market?

Major companies operating in the onchocerciasis treatment market are Merck & Co. Inc., Teva Pharmaceutical Industries Limited, Hetero Labs Limited, Sun Pharmaceutical Industries Limited, Intas Pharmaceuticals Limited, Dr. Reddy’s Laboratories Inc., Cipla Limited, Endo Inc., Lupin Limited, Instituto de Tecnologia em Imunobiológicos Bio-Manguinhos – Fundação Oswaldo Cruz (Fiocruz), AMGIS Lifescience Ltd., Drugs for Neglected Diseases initiative (DNDi), Rakshit Drugs Pvt. Ltd., Hangzhou Longshine Bio-Tech Co. Ltd., OREX Pharma Private Limited, Angle Bio Pharma Pvt. Ltd., Senores Pharmaceuticals Inc., Avenacy LLC, Dolphin Pharma, Cerata Pharmaceuticals Inc.

What Are the Key Drivers of the Onchocerciasis Treatment Market?

An increase in people suffering from eye-related problems is anticipated to pave the way for the expansion of the onchocerciasis treatment market. Eye-related issues encompass a range of conditions impacting vision and eye health, such as infections, injuries, and chronic diseases like cataracts or glaucoma. The surge in these issues is predominantly due to extended screen time and long-lasting exposure to digital devices. Treatments for onchocerciasis aid in staving off and managing vision impairment and blindness in patients by eradicating the parasitic infection leading to inflammation and harm to ocular tissues. For example, the Centers for Disease Control and Prevention (CDC), a United States-based public health institution, reported in May 2024 that roughly 20.5 million Americans aged 40 and above suffered from cataracts in at least one eye, making up 17.2% of that demographic. By 2028, it is projected that nearly 30 million individuals will be affected by cataracts. Therefore, the growing occurrence of eye-related health conditions fuels the growth of the onchocerciasis treatment market. The Growing Incidence of Surgical Interventions Spurs Market Growth due to Increasing Instances Requiring Advanced Disease Control

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=24634&type=smp

What Are the Key Market Segments in the Onchocerciasis Treatment Industry?

The onchocerciasis treatment market covered in this report is segmented –

1) By Drug Type: Ivermectin, Doxycycline, Albendazole, Moxidectin

2) By Treatment Strategy: Mass Drug Administration (MDA), Targeted Treatment

3) By Mode Of Administration: Oral, Injectables, Topical

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End User: Hospitals And Clinics, Home Care Settings, Government And Non-Governmental Programs

Subsegments:

1) By Ivermectin: Oral Tablets, Community-Based Mass Drug Administration (MDA) Kits, Fixed-Dose Combination Therapies, Pediatric Formulations

2) By Doxycycline: Oral Capsules, Extended-Release Tablets, Combination With Anti-Wolbachia Therapy, Hospital-Based Prescription Treatments

3) By Albendazole: Single-Dose Oral Tablets, Combination Therapy With Ivermectin, Government-Supplied Preventive Chemotherapy Packages, Over-The-Counter (OTC) Formulations In Endemic Areas

4) By Moxidectin: Oral Tablets, Long-Acting Formulations, Adult-Only Dosing Regimens, Clinical Trial-Based Access Programs

What Are the Latest Trends in the Onchocerciasis Treatment Market?

Leading corporations in the onchocerciasis treatment sector are concentrating on the creation of unique antiparasitic drugs to enhance the efficacy of treatments and decrease their duration. These are drugs formulated to eradicate or deter parasites like worms and protozoa, which result in human infections. For example, in December 2024, Medicines Development for Global Health (MDGH), a non-profit biopharmaceutical firm based in Australia, obtained Ghana Food and Drugs Authority’s (FDA) authorization for 2 mg Moxidectin oral tablets to cure river blindness in people who are 4 years old and above. The go-ahead allows Ghana to run community-based mass drug distribution programmes featuring moxidectin, providing higher potency and enduring effect in comparison to ivermectin. MDGH intends to increase availability to a new efficient onchocerciasis treatment through this approval, facilitating large-scale community operations in regions where the disease is prevalent.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/onchocerciasis-treatment-global-market-report

What Are the Key Regional Markets in the Onchocerciasis Treatment Industry?

North America was the largest region in the onchocerciasis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the onchocerciasis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=24634

This Report Delivers Insight On:

1. How big is the onchocerciasis treatment market, and how is it changing globally?

2. Who are the major companies in the onchocerciasis treatment market, and how are they performing?

3. What are the key opportunities and risks in the onchocerciasis treatment market right now?

4. Which products or customer segments are growing the most in the onchocerciasis treatment market?

5. What factors are helping or slowing down the growth of the onchocerciasis treatment market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model